Incretin Atlas › Trials › SURMOUNT-2
SURMOUNT-2
Tirzepatide · t2d
Design
- Molecule(s)
- Tirzepatide
- Population
- t2d
- Official title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2021-03 → 2023-03
- Participants
- 938
- Duration
- 72 weeks
- Registry
- NCT04657003
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tirzepatide 15 mg | t2d | 72 | 938 | −15.7 % vs −3.3 % Δ −12.4 pp | −14.7 % vs −3.2 % Δ −11.5 pp | −2.1 vs −0.5 | 7.4 vs 3.8 | 13.8 vs 14.9 | 21.9 vs 6.3 | 13.2 vs 3.2 | 8.7 vs 7.3 | — | verified |
| tirzepatide 10 mg | t2d | 72 | 938 | −13.4 % vs −3.3 % Δ −10.1 pp | −12.8 % vs −3.2 % Δ −9.6 pp | −2.1 vs −0.5 | 3.8 vs 3.8 | 9.3 vs 14.9 | 20.2 vs 6.3 | 10.9 vs 3.2 | 5.8 vs 7.3 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (11)
- tirzepatide 15 mg · nausea · Table 3
| Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
- tirzepatide 15 mg · vomiting · Table 3
| Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
- tirzepatide 15 mg · disc_any · Figure 1 (trial profile)
| 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
- tirzepatide 15 mg · sae · Table 3
| Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
- tirzepatide 15 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
| Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
- tirzepatide 15 mg · hba1c · Table 2 + Results
| Change in HbA₁c, % | -2·07 (0·06) | -2·08 (0·07) | -0·51 (0·07) | ETD -1·55 (-1·74, -1·37); p<0·0001 | ETD -1·57 (-1·76, -1·37); p<0·0001 |
- tirzepatide 10 mg · nausea · Table 3
| Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
- tirzepatide 10 mg · vomiting · Table 3
| Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
- tirzepatide 10 mg · disc_any · Figure 1 (trial profile)
| 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
- tirzepatide 10 mg · sae · Table 3
| Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
- tirzepatide 10 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
| Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
Primary sources
- Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. PMID: 37385275.
- Eli Lilly and Company. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) (SURMOUNT-2). ClinicalTrials.gov identifier NCT04657003. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04657003
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURMOUNT-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.